BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 8970403)

  • 1. Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
    Labinaz M; Sketch MH; Stebbins AL; DeFranco AC; Holmes DR; Kleiman NS; Betriu A; Rutsch WR; Vahanian A; Topol EJ; Califf RM
    Am J Cardiol; 1996 Dec; 78(12):1338-44. PubMed ID: 8970403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials.
    Hudson MP; Granger CB; Topol EJ; Pieper KS; Armstrong PW; Barbash GI; Guerci AD; Vahanian A; Califf RM; Ohman EM
    Circulation; 2001 Sep; 104(11):1229-35. PubMed ID: 11551872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Mak KH; Moliterno DJ; Granger CB; Miller DP; White HD; Wilcox RG; Califf RM; Topol EJ
    J Am Coll Cardiol; 1997 Jul; 30(1):171-9. PubMed ID: 9207639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction.
    Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators
    N Engl J Med; 1997 Jun; 336(23):1621-8. PubMed ID: 9173270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies.
    Barbash GI; Birnbaum Y; Bogaerts K; Hudson M; Lesaffre E; Fu Y; Goodman S; Houbracken K; Munsters K; Granger CB; Pieper K; Califf RM; Topol EJ; Van De Werf F
    Circulation; 2001 Feb; 103(7):954-60. PubMed ID: 11181469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators.
    Barbagelata A; Califf RM; Sgarbossa EB; Goodman SG; Stebbins AL; Granger CB; Suarez LD; Borruel M; Gates K; Starr S; Wagner GS
    J Am Coll Cardiol; 1997 Mar; 29(4):770-7. PubMed ID: 9091523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study.
    Berger PB; Holmes DR; Stebbins AL; Bates ER; Califf RM; Topol EJ
    Circulation; 1997 Jul; 96(1):122-7. PubMed ID: 9236426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term follow-up of patients with acute myocardial infarction treated with primary angioplasty or thrombolysis. Results of the MITRA trial].
    Zhan R; Schiele R; Schneider S; Gitt AK; Heer T; Wienbergen H; Seidl K; Glunz HG; Hauptmann KE; Voigtländer T; Gottwik M; Senges J;
    Z Kardiol; 2002 Jan; 91(1):49-57. PubMed ID: 11963207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to treatment with thrombolytic therapy: determinants and effect on short-term nonfatal outcomes of acute myocardial infarction. Canadian GUSTO Investigators. Global Utilization of Streptokinase and + PA for Occluded Coronary Arteries.
    Cox JL; Lee E; Langer A; Armstrong PW; Naylor CD
    CMAJ; 1997 Feb; 156(4):497-505. PubMed ID: 9054819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Tardiff BE; Califf RM; Morris D; Bates E; Woodlief LH; Lee KL; Green C; Rutsch W; Betriu A; Aylward PE; Topol EJ
    J Am Coll Cardiol; 1997 Feb; 29(2):240-9. PubMed ID: 9014973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial.
    White HD; Barbash GI; Califf RM; Simes RJ; Granger CB; Weaver WD; Kleiman NS; Aylward PE; Gore JM; Vahanian A; Lee KL; Ross AM; Topol EJ
    Circulation; 1996 Oct; 94(8):1826-33. PubMed ID: 8873656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.
    Metz BK; White HD; Granger CB; Simes RJ; Armstrong PW; Hirsh J; Fuster V; MacAulay CM; Califf RM; Topol EJ
    J Am Coll Cardiol; 1998 Jun; 31(7):1493-8. PubMed ID: 9626825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of recurrent ischemia after reperfusion therapy in acute myocardial infarction: a comparison of thrombolytic therapy and primary angioplasty.
    Stone GW; Grines CL; Browne KF; Marco J; Rothbaum D; O'Keefe J; Hartzler GO; Overlie P; Donohue B; Chelliah N
    J Am Coll Cardiol; 1995 Jul; 26(1):66-72. PubMed ID: 7797777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of acute myocardial infarction location on in-hospital and late outcome after primary percutaneous transluminal coronary angioplasty versus tissue plasminogen activator therapy.
    Stone GW; Grines CL; Browne KF; Marco J; Rothbaum D; O'Keefe J; Hartzler GO; Overlie P; Donohue B; Chelliah N; Vlietstra R; Puchrowicz-Ochocki S; O'Neill WW
    Am J Cardiol; 1996 Jul; 78(1):19-25. PubMed ID: 8712112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial.
    Holmes DR; Califf RM; Van de Werf F; Berger PB; Bates ER; Simoons ML; White HD; Thompson TD; Topol EJ
    Lancet; 1997 Jan; 349(9045):75-8. PubMed ID: 8996417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review.
    Weaver WD; Simes RJ; Betriu A; Grines CL; Zijlstra F; Garcia E; Grinfeld L; Gibbons RJ; Ribeiro EE; DeWood MA; Ribichini F
    JAMA; 1997 Dec; 278(23):2093-8. PubMed ID: 9403425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
    Steg PG; Laperche T; Golmard JL; Juliard JM; Benamer H; Himbert D; Aubry P
    J Am Coll Cardiol; 1998 Mar; 31(4):776-9. PubMed ID: 9525545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
    Topol EJ; Ohman EM; Armstrong PW; Wilcox R; Skene AM; Aylward P; Simes J; Dalby A; Betriu A; Bode C; White HD; Hochman JS; Emanuelson H; Vahanian A; Sapp S; Stebbins A; Moliterno DJ; Califf RM
    Circulation; 2000 Oct; 102(15):1761-5. PubMed ID: 11023929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Van de Werf F; Topol EJ; Lee KL; Woodlief LH; Granger CB; Armstrong PW; Barbash GI; Hampton JR; Guerci A; Simes RJ
    JAMA; 1995 May 24-31; 273(20):1586-91. PubMed ID: 7745771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.